Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes.
Clenbuterol, a compound classified as a beta2-adrenoceptor (AR) agonist, has been employed in combination with left ventricular assist devices (LVADs) to treat patients with severe heart failure. Previous studies have shown that chronic administration of clenbuterol affects cardiac excitation-contraction coupling. However, the acute effects of clenbuterol and the signaling pathway involved remain undefined. We investigated the acute effects of clenbuterol on isolated ventricular myocyte sarcomere shortening, Ca2+ transients, and L-type Ca2+ current and compared these effects to two other clinically used beta2-AR agonists: fenoterol and salbutamol. Clenbuterol (30 microM) produced a negative inotropic response, whereas fenoterol showed a positive inotropic response. Salbutamol had no significant effects. Clenbuterol reduced Ca2+ transient amplitude and L-type Ca2+ current. Selective beta1-AR blockade did not affect the action of clenbuterol on sarcomere shortening but significantly reduced contractility in the presence of fenoterol and salbutamol (P < 0.05). Incubation with 2 microg/ml pertussis toxin significantly reduced the negative inotropic effects of 30 microM clenbuterol. In addition, overexpression of inhibitory G protein (Gi) by adenoviral transfection induced a stronger clenbuterol-mediated negative inotropic effect, suggesting the involvement of the Gi protein. We conclude that clenbuterol does not increase and, at high concentrations, significantly depresses contractility of isolated ventricular myocytes, an effect not seen with fenoterol or salbutamol. In its negative inotropism, clenbuterol predominantly acts through Gi, and the consequent downstream signaling pathways activation may explain the beneficial effects observed during chronic administration of clenbuterol in patients treated with LVADs.
Siedlecka
U
U
Heart Science Centre, National Heart & Lung Institute, Imperial College, London, United Kingdom.
Arora
M
M
Kolettis
T
T
Soppa
G K R
GK
Lee
J
J
Stagg
M A
MA
Harding
S E
SE
Yacoub
M H
MH
Terracciano
C M N
CM
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000420:Albuterol / Q000494:pharmacology; D000818:Animals; D020746:Calcium Channels, L-Type / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects*; D002478:Cells, Cultured; D002976:Clenbuterol / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005280:Fenoterol / Q000494:pharmacology; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000235:genetics / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism; D006706:Homeostasis; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009200:Myocardial Contraction / Q000187:drug effects*; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D012518:Sarcomeres / Q000187:drug effects / Q000378:metabolism; D014162:Transfection
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D020746:Calcium Channels, L-Type; D018727:Muscarinic Antagonists; D005280:Fenoterol; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D000420:Albuterol; D002976:Clenbuterol
J Pharmacol Exp Ther. 2005 Dec;315(3):1203-11
16135702
J Heart Lung Transplant. 2006 Sep;25(9):1084-90
16962470
Circulation. 1998 Dec 1;98(22):2383-9
9832482
Pharmacol Ther. 1993 Dec;60(3):405-30
7915424
Ann Thorac Surg. 1999 Aug;68(2):734-41
10475480
J Pharmacol Exp Ther. 2006 May;317(2):553-61
16421285
Muscle Nerve. 2001 Dec;24(12):1687-91
11745978
N Engl J Med. 2003 May 15;348(20):2007-18
12748317
Circulation. 1993 Sep;88(3):854-63
8102599
Circulation. 2003 Sep 30;108(13):1633-9
12975249
J Biochem Mol Biol. 2007 Jul 31;40(4):525-31
17669268
Biochem Biophys Res Commun. 2007 Jun 15;357(4):889-95
17466269
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1607-12
11171998
Circulation. 2007 May 15;115(19):2497-505
17485581
Circulation. 1999 Nov 30;100(22):2210-2
10577992
J Clin Invest. 1996 Jul 15;98(2):556-62
8755668
N Engl J Med. 2001 Nov 15;345(20):1435-43
11794191
Sci STKE. 2001 Oct 16;2001(104):re15
11604549
J Cell Biol. 2001 Aug 20;154(4):753-61
11514589
Biochem J. 1989 Dec 1;264(2):573-9
2481447
Pharmacol Rev. 1999 Dec;51(4):651-90
10581327
Biochem Biophys Res Commun. 2002 Sep 20;297(2):302-8
12237118
Congest Heart Fail. 2004 Jul-Aug;10(4):181-5; quiz 186-7
15314476
Biophys J. 2000 Nov;79(5):2547-56
11053129
J Biol Chem. 1999 Jul 30;274(31):22048-52
10419531
Cardiovasc Res. 1998 Jan;37(1):115-22
9539865
Proc Natl Acad Sci U S A. 1985 Feb;82(3):727-31
3919382
Circulation. 2002 May 28;105(21):2497-503
12034656
J Physiol. 2003 Nov 15;553(Pt 1):229-42
12949221
Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1468-76
15528231
J Pharmacol Sci. 2007 Jun;104(2):146-52
17558185
Circ Res. 2000 Dec 8;87(12):1172-9
11110775
Circulation. 2005 Aug 30;112(9 Suppl):I51-6
16159865
Rapid Commun Mass Spectrom. 2005;19(23):3603-6
16276488
J Biol Chem. 1997 Aug 1;272(31):19401-7
9235939
Transplant Proc. 2001 Aug;33(5):2762-4
11498152
Circulation. 1997 Oct 7;96(7):2239-46
9337196
Exp Neurol. 2004 Jun;187(2):460-7
15144872
Pharmacol Ther. 2006 Sep;111(3):652-73
16480771
Eur Heart J. 2001 Apr;22(7):534-40
11259141
Cardiovasc Res. 2006 Dec 1;72(3):422-9
17054929
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14475-80
14612574
Eur J Clin Pharmacol. 1975 Apr 4;8(3-4):189-95
9295
N Engl J Med. 2006 Nov 2;355(18):1873-84
17079761
Circulation. 1995 Nov 1;92(9 Suppl):II483-9
7586459
Biophys J. 2003 Nov;85(5):3388-96
14581240